Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi’s Taxotere Gets Priority Review For Head And Neck Cancer Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval would place the taxane in more direct competition with ImClone/Bristol’s Erbitux.
Advertisement

Related Content

Sanofi-Aventis’ Taxotere Adds New Head And Neck Cancer Indication
Sanofi-Aventis’ Taxotere Adds New Head And Neck Cancer Indication
Erbitux Shows Survival Benefit With Chemo In First-Line Metastatic Head & Neck Cancer
Erbitux Shows Survival Benefit With Chemo In First-Line Metastatic Head & Neck Cancer

Topics

Advertisement
UsernamePublicRestriction

Register

PS066249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel